Breast Cancer | Specialty

ESR1 Mutations Take Center Stage in Metastatic ER-Positive Breast Cancer

August 1st 2018

Despite gaps in current knowledge, investigators are already working toward the development of novel treatment strategies to combat the effects of ESR1 mutations.

Dr. Ligibel on the Impact of Diet and Exercise on Breast Cancer Recurrence Risk

August 1st 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute, discusses the impact of diet and exercise on the risk of breast cancer recurrence.

Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer

August 1st 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.

Dr. Adams on Combinatorial Approaches in Triple-Negative Breast Cancer

August 1st 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses combinatorial approaches in triple-negative breast cancer.

Dr. Yardley on the D-CARE Trial in Women With High-Risk Early Breast Cancer

July 31st 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the D-CARE trial in women with high-risk early breast cancer.

Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 30th 2018

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer.

Dr. Sparano on Application of Liquid Biopsies in Breast Cancer

July 30th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

Wolmark's Passion for Evidence-Based Medicine Helped Transform Cancer Care

July 30th 2018

Norman Wolmark, MD, a 2017 Giants of Cancer Care® award winner in the Breast Cancer category, played a pivotal role in building the clinical trials program at the National Surgical Adjuvant Breast and Bowel Project.

Dr. Woodward on Proton Radiotherapy in Breast Cancer

July 27th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses proton radiotherapy in breast cancer.

Immunotherapy Remains Focal Point in TNBC

July 27th 2018

Sylvia Adams, MD, discusses the path forward for immunotherapy in triple-negative breast cancer.

Dr. Esserman on Personalized Screenings for Breast Cancer

July 26th 2018

Laura Esserman, MD, MBA, professor, University of California, San Francisco, discusses personalized versus annual screenings for breast cancer.

Future of CDK4/6 Inhibition in HR+ Breast Cancer

July 26th 2018

Abemaciclib Monotherapy's Role in HR+ Breast Cancer

July 26th 2018

Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

July 26th 2018

HR+ Breast Cancer: Factors in Selecting a CDK4/6 Inhibitor

July 26th 2018

HR+ Breast Cancer: CDK4/6 Inhibitors & Sites of Metastasis

July 26th 2018

HR+ Breast Cancer: Risk-Stratifying to CDK4/6 Inhibitors

July 26th 2018

HR+ Breast Cancer: Prognostic Subgroups in MONARCH Trials

July 26th 2018

HR+ Breast Cancer: Differences Between CDK4/6 Inhibitors

July 26th 2018

Considering CDK4/6 Inhibitors in Advanced Breast Cancer

July 26th 2018